Santen SAS
Quick facts
Marketed products
- NOVA63035 "Corticosteroid" · Ophthalmology or Dermatology
NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.
Phase 3 pipeline
- DE-130A · Ophthalmology
DE-130A is a small-molecule inhibitor designed to modulate intraocular pressure and inflammation in the eye. - DE-130A/DE-130A · Ophthalmology
DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension. - Masked Ikervis · Ophthalmology
Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface. - NOVA22007 · Ophthalmology
NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye. - NOVA22007 ''Ciclosporin'' · Immunology
Ciclosporin suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing inflammatory immune responses. - NOVA22007 (Ciclosporin 0.1%) · Ophthalmology
Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. - Open-label Ikervis · Ophthalmology
Ikervis is a lipid emulsion eye drop that reduces inflammation and promotes tear production in dry eye disease by delivering cyclosporine to the ocular surface. - Xalatan®/DE-130A · Ophthalmology
Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.
Phase 2 pipeline
- Cyclosporine NOVA22007 0.05% · Ophthalmology
Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation. - Cyclosporine NOVA22007 0.1%
- NOVA22007 ''Cyclosporine''
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Santen SAS
What are Santen SAS's marketed drugs?
Top marketed products include NOVA63035 "Corticosteroid".
What is Santen SAS's pipeline?
Santen SAS has 8 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include DE-130A, DE-130A/DE-130A, Masked Ikervis, NOVA22007.
Related
- NOVA63035 "Corticosteroid" · Ophthalmology or Dermatology
- Sector hub: All tracked pharma companies